Evidence map›Paper›PMID 40558441›Full record

ReviewBiosensors2025

Surface Plasmon Resonance Aptasensors: Emerging Design and Deployment Landscape.

Fahd Khalid-Salako, Hasan Kurt, Meral Yüce

Abstract readReview
In one paragraph

Review in Biosensors, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Review
  3. EnterohemorrhagicACS omega · 2026
    Article
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Fahd Khalid-SalakoSabanci University Nanotechnology Research and Application Center, 34956 Istanbul, Türkiye.ORCID 0000-0003-4795-2423
Hasan KurtSabanci University Nanotechnology Research and Application Center, 34956 Istanbul, Türkiye.
Meral YüceSabanci University Nanotechnology Research and Application Center, 34956 Istanbul, Türkiye.ORCID 0000-0003-0393-1225

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

SPR biosensors operate on the principle of evanescent wave propagation at metal-dielectric interfaces in total internal reflection conditions, with consequent photonic energy attenuation. This plasmonic excitation occurs in specific conditions of incident light wavelength, angle, and the dielectric refractive index. This principle has been the basis for SPR-based biosensor setups wherein mass/concentration-induced changes in the refractive indices of dielectric media reflect as plasmonic resonance condition changes quantitatively reported as arbitrary response units. SPR biosensors operating on this conceptual framework have been designed to study biomolecular interactions with real-time readout and in label-free setups, providing key kinetic characterization that has been valuable in various applications. SPR biosensors often feature antibodies as target affinity probes. Notably, the operational challenges encountered with antibodies have led to the development of aptamers-oligonucleotide biomolecules rationally designed to adopt tertiary structures, enabling high affinity and specific binding to a wide range of targets. Aptamers have been extensively adopted in SPR biosensor setups with promising clinical and industrial prospects. In this paper, we explore the growing literature on SPR setups featuring aptamers, specifically providing expert commentary on the current state and future implications of these SPR aptasensors for drug discovery as well as disease diagnosis and monitoring.

Indexed as

Aptamers, NucleotideBiosensing TechniquesSurface Plasmon ResonanceHumansAptamers, Nucleotideaptamersbiosensorsdrug discoveryligandsSELEXsurface plasmon resonance

Identifiers

PMID40558441
PMCPMC12190323

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.